The following are links to KEI’s work on the coronavirus pandemic.
- March 5, 2020. Unreasonable pricing and the “Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020”
- March 14, 2020. Three areas in Section 202 of the Bayh-Dole Act that require action to ensure sufficient rights in patents on coronavirus relevant inventions.
- March 16, 2020. Patent Troll Files Lawsuit to Block Possible Coronavirus Diagnostic.
- March 17, 2020. Chilean Chamber of Deputies approves resolution for compulsory licenses for patents relating to the coronavirus virus.
- March 20, 2020. Legislative Committee in Ecuador approves resolution on compulsory licensing of patents relating to the coronavirus.
- March 20, 2020. Kathryn Ardizzone, Role of the U.S. Federal Government in the Development of GS-5734/Remdesivir, KEI Briefing Note 2020:1.
- March 23, 2020. Israel issues compulsory license to allow government to import generic versions of Kaletra.
- March 23, 2020. KEI Letter to Speaker Pelosi Regarding Use of “Other Transaction Authority” (OTA) in Coronavirus Bill to Escape Bayh-Dole Public Interest Safeguards.
- March 23, 2020. FDA gives Gilead a seven year regulatory monopoly for remdesivir to treat COVID-19, on grounds it is an “Orphan” treating a rare disease.
- March 23, 2020. President and Minister of Health of Costa Rica ask WHO to create global pool for rights in COVID-19 related technologies.
- March 24, 2020. House Coronavirus Bill Provision Could be Used for COVID-19/Coronavirus-Related R&D without Public-Interest Safeguards.
- March 25, 2020. FDA States Submission Date of Gilead’s Coronavirus Treatment Orphan Status Application is ‘Confidential’.
- March 27, 2020. Open letter to the World Health Organization (WHO) and its Member States on the proposal by Costa Rica to create a global pool for rights in the data, knowledge and technologies useful in the prevention, detection and treatment of the coronavirus/COVID-19 pandemic
KEI is also taking a daily snapshot of COVID-19 confirmed cases in countries reported by JHU, here.
KEI has filed multiple Freedom of Information Act requests on issues related to the coronavirus pandemic, including on government funding of candidates for potential treatment of COVID-19. A list of all related FOIA requests and their current statuses is available here.